Current Partners
In January 2013, we entered into a collaboration agreement with Algeta ASA, for the development of epratuzumab conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload.
Learn MoreWe believe developing collaborations and partnerships is a key part of our strategy to successfully leveraging our portfolio of therapeutic products and platform technologies.
In January 2013, we entered into a collaboration agreement with Algeta ASA, for the development of epratuzumab conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload.
Learn More
We have accumulated an extensive patent portfolio in the course of our research in the areas of Multivalent Bispecific Antibodies, F-18 Labeling, DOCK-AND-LOCK™, Antibody-Drug Conjugates, Antibody-Drug Conjugate Linker, and T-cell Redirecting Antibodies, which we believe constitutes a very valuable business asset.